<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "http://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID></PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle></ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal></Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <ForeName>Ioanna</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
          </JournalIssue>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume></Volume>
            <Issue></Issue>
            <PubDate></PubDate>
          </JournalIssue>
          <Title></Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract></Abstract>
        <AuthorList CompleteYN="Y"></AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList></MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year></Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText></AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y"></Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading></MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schreml</LastName>
            <ForeName></ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gouni-Berthold</LastName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N"></DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
  
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID>28618900</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>12</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1875-533X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>25</Volume>
            <Issue>13</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>Current medicinal chemistry</Title>
          <ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.</ArticleTitle>
        <Pagination>
          <MedlinePgn>1538-1548</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2174/0929867324666170616111647</ELocationID>
        <Abstract>
          <AbstractText>Statin</AbstractText>
          <AbstractText>intolerance</AbstractText>
          <CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <AffiliationInfo>
              <Affiliation>Institute for Human Genetics, University of Cologne, Kerpener Str. 34, 50931, Cologne, Germany.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName></LastName>
            <ForeName></ForeName>
            <Initials></Initials>
            <AffiliationInfo>
              <Affiliation>Polyclinic for Endocrinology, Diabetes and Preventive Medicine (PEDP), University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United Arab Emirates</Country>
        <MedlineTA>Curr Med Chem</MedlineTA>
        <NlmUniqueID>9440157</NlmUniqueID>
        <ISSNLinking>0929-8673</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="C472125">PCSK9 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.21.-</RegistryNumber>
          <NameOfSubstance UI="D000071449">Proprotein Convertase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LKC0U3A8NJ</RegistryNumber>
          <NameOfSubstance UI="C577155">evolocumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PP0SHH6V16</RegistryNumber>
          <NameOfSubstance UI="C571059">alirocumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alirocumab</Keyword>
        <Keyword MajorTopicYN="N">PCSK9</Keyword>
        <Keyword MajorTopicYN="N">anti-PCSK9 antibody</Keyword>
        <Keyword MajorTopicYN="N">evolocumab</Keyword>
        <Keyword MajorTopicYN="N">ezetimibe</Keyword>
        <Keyword MajorTopicYN="N">statin</Keyword>
        <Keyword MajorTopicYN="N">statin intolerance.</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>07</Month>
          <Day>05</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>2</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28618994</ArticleId>
        <ArticleId IdType="pii">CMC-EPUB-84173</ArticleId>
        <ArticleId IdType="doi">10.2174/0929867324666170616111647</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>